Related Experiment Video
Updated: Apr 12, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
1.4K
Rheumatoid Arthritis - Anti-TNF
Khaldoun Chaabo1, Bruce Kirkham1
1Rheumatology Department, Guy's & St Thomas' NHS Foundation Trust, London SE1 9RT, UK.
International Immunopharmacology
|May 13, 2015
Summary
This review covers the optimal use of Tumor Necrosis Factor (TNF) inhibitor therapy in Rheumatoid Arthritis (RA). It highlights early RA management, anti-drug antibodies, and long-term safety and dosage strategies for effective treatment.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Rheumatoid Arthritis (RA) is a chronic autoimmune disease.
- TNF inhibitors (TNFi) are a cornerstone therapy for RA.
- Optimal TNFi use requires understanding evolving strategies.
Purpose of the Study:
- To review recent advancements in TNF inhibitor therapy for RA.
- To provide guidance on the best use of TNFi in clinical practice.
- To consolidate current knowledge on TNFi management.
Main Methods:
- Literature review of recent studies on TNFi in RA.
- Analysis of data concerning early RA management with TNFi.
- Evaluation of information on anti-drug antibodies and long-term TNFi use.
Main Results:
- TNFi therapy plays a crucial role in early RA management.
- Anti-drug antibodies can impact TNFi efficacy and safety.
- Updated safety profiles and optimal dosing regimens are essential for long-term management.
Conclusions:
- Recent data support the strategic use of TNFi in early RA.
- Monitoring for anti-drug antibodies is important for optimizing TNFi therapy.
- Adherence to updated safety and dosage guidelines ensures effective long-term RA management.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
800
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
800
01:24T Cell Types and Functions
3.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.4K
01:21Rheumatic Heart Disease III: Medical Management
523
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
523
01:20The JAK-STAT Signaling Pathway
14.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
14.1K
01:11Genome-wide Association Studies-GWAS
16.8K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
16.8K
01:20Rheumatic Heart Disease IV: Nursing Management
465
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
465